StemiRNA Therapeutics obtains 10-million-yuan investment from Junshi Bio

HKEx-listed company Junshi Bio has invested 10 million yuan in Stemirna Therapeutics, a Shanghai company developing mRNA vaccine therapeutics for cancers. Junshi, which made the investment as part of an A+ round, acquired a 3% stake in Stemirna.

HKEx-listed company Junshi Bio has invested 10 million yuan in Stemirna Therapeutics, a Shanghai company developing mRNA vaccine therapeutics for cancers. Junshi, which made the investment as part of an A+ round, acquired a 3% stake in Stemirna.

Stemirna is one of the earliest platform enterprises focusing on mRNA technology-based drug development in China. This investment will help both parties to draw on each other’s strengths. The two companies will jointly develop novel drugs and combination therapies, which will have a positive impact on the company’s business development.

Li Hangwen, CEO of Stemirna said, “The mRNA tumor vaccine is just the company’s first product. We are also actively expanding to the fields of infectious diseases, such as influenza, MERS virus, etc. In the meantime, we will also maintain an active presence in the fields of tumor immunotherapy, antibodies, rare diseases and genetic therapy. In addition to treatment, prevention will also be another aspect we need to focus on. “

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/06/stemirna-therapeutics-obtains-10-million-yuan-investment-from-junshi-bio/.

Leave a Reply

Your email address will not be published. Required fields are marked *